Lei XH, Yang YQ, Ma CY, Duan EK. Induction of differentiation of human stem cells ex vivo: Toward large-scale platelet production. World J Stem Cells 2019; 11(9): 666-676 [PMID: 31616542 DOI: 10.4252/wjsc.v11.i9.666]
Corresponding Author of This Article
Xiao-Hua Lei, PhD, Senior Engineer, State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, 1 Beichen West Road, Chaoyang District, Beijing 100101, China. leixh@ioz.ac.cn
Research Domain of This Article
Cell Biology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Xiao-Hua Lei, Chi-Yuan Ma, En-Kui Duan, State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
Yi-Qing Yang, Faculty of Laboratory Medical Science, Hebei North University, Zhangjiakou 075000, Hebei Province, China
Author contributions: Lei XH generated the figures and wrote the manuscript; Yang YQ contributed to the writing of the manuscript; Ma CY revised the manuscript; Duan EK designed the aim of the editorial and wrote the manuscript.
Supported bythe National Natural Science Foundation of China Grants, No. 31600683 and No. U1738103; and Strategic Priority Research Program of the Chinese Academy of Sciences, No. XDA15014000.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Xiao-Hua Lei, PhD, Senior Engineer, State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, 1 Beichen West Road, Chaoyang District, Beijing 100101, China. leixh@ioz.ac.cn
Telephone: + 86-10-64807308 Fax: + 86-10-64807308
Received: February 15, 2019 Peer-review started: February 15, 2019 First decision: May 9, 2019 Revised: May 12, 2019 Accepted: August 26, 2019 Article in press: August 26, 2019 Published online: September 26, 2019 Processing time: 222 Days and 12.9 Hours
Abstract
Platelet transfusion is one of the most reliable strategies to cure patients suffering from thrombocytopenia or platelet dysfunction. With the increasing demand for transfusion, however, there is an undersupply of donors to provide the platelet source. Thus, scientists have sought to design methods for deriving clinical-scale platelets ex vivo. Although there has been considerable success ex vivo in the generation of transformative platelets produced by human stem cells (SCs), the platelet yields achieved using these strategies have not been adequate for clinical application. In this review, we provide an overview of the developmental process of megakaryocytes and the production of platelets in vivo and ex vivo, recapitulate the key advances in the production of SC-derived platelets using several SC sources, and discuss some strategies that apply three-dimensional bioreactor devices and biochemical factors synergistically to improve the generation of large-scale platelets for use in future biomedical and clinical settings.
Core tip: Platelets derived from voluntary blood donation pose some challenges, such as susceptibility to pathogen contamination, short preservation time and difficulty in satisfying the increasing number of patients requiring platelet transfusion. Thus, seeking a safe and reliable alternative source of platelets is an effective solution.
